Funder
National Institutes of Health
Reference5 articles.
1. Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial;Bassetti;Lancet Infect Dis,2021
2. M100: performance standards for antimicrobial susceptibility testing,2023
3. Performance evaluation of the UMICⓇ Cefiderocol to determine MIC in Gram-negative bacteria;Dortet;J Antimicrob Chemother,2023
4. Performance of discs, sensititre EUMDROXF microplates and MTS gradient strips for the determination of the susceptibility of multidrug-resistant Pseudomonas aeruginosa to cefiderocol;Devoos;Clin Microbiol Infect,2023
5. Comparison of fast Fourier transform infrared spectroscopy biotyping with whole genome sequencing-based genotyping in common nosocomial pathogens;Teng;Anal Bioanal Chem,2022